Journal List > J Korean Acad Nurs > v.45(6) > 1003120

TOOLS
Chu, Lee, Lee, and Cleeland: Properties of the Measures to Assess Oxaliplatin-induced Peripheral Neuropathy: A Literature Review
Review Article

Journal of Korean Academy of Nursing 2015; 45(6): 783-801.

Published online: 31 December 2015

DOI: https://doi.org/10.4040/jkan.2015.45.6.783

Properties of the Measures to Assess Oxaliplatin-induced Peripheral Neuropathy: A Literature Review

Sang Hui Chu1, Yoon Ju Lee2, Young Joo Lee3, Charles S. Cleeland4

1College of Nursing·Mo-Im Kim Nursing Research Institute, Yonsei University, Seoul, Korea.

2College of Nursing, Pusan National University, Yangsan, Korea.

3Graduate School, Yonsei University, Seoul, Korea.

4Department of Symptom Research, The University of Texas M.D. Anderson Cancer Center, Texas, USA.

Address reprint requests to: Lee, Yoon Ju. College of Nursing, Pusan National University, 49 Busandaehak-ro, Mulgeum-eup, Yangsan 50612, Korea. Tel: +82-51-510-8361, Fax: +82-51-510-8308, lyj@pusan.ac.kr

Received 7 May 2015       Revised 27 May 2015       Accepted 16 September 2015

© 2015 Korean Society of Nursing Science

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution NoDerivs License. (http://creativecommons.org/licenses/by-nd/4.0/) If the original work is properly cited and retained without any modification or reproduction, it can be used and re-distributed in any format and medium.

Abstract

Purpose

The purpose of this study is to provide a comprehensive overview of the various measures available for assessment of oxaliplatin-induced peripheral neuropathy (OXLIPN) and to evaluate the measurement properties of each assessment tool.

Methods

A systematic review was conducted to identify existing measures for OXLIPN found in the databases of PubMed, Cochrane Library, Embase, RISS and KoreaMed. The quality of the 24 identified tools was evaluated based on their properties of measurement including content validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, floor-ceiling effects and interpretability.

Results

Ten (41.7%) of the 24 tools were identified as specific measures for assessing OXLIPN and the most popular type of measures were clinical grading systems by clinicians (58.3%) and only 29.2% of measures were identified as patient reported outcomes. The most frequently used tool was National Cancer Institute-Common Toxicity Criteria (NCI-CTC), but the validity of NCI-CTC has not been reported appropriately. Overall, the Neuropathic Pain Symptom Inventory (NPSI) received the best psychometric scores, and the Chemotherapy-induced Peripheral Neuropathy Assessment Tool (CIPNAT) and Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group-neurotoxicity-12 (FACT/GOG-Ntx-12) followed NPSI.

Conclusion

To select appropriate measure, evidences should be accumulated through the clinical use of tools. Therefore, practitioner and researchers are urged to report relevant statistics required for the validation of the currently used measures for assessment of OXLIPN.

Keywords: Oxaliplatin, Peripheral nervous system diseases, Symptom assessment, Psychometrics

Figures and Tables

Figure 1

Flow of review process.

jkan-45-783-g001
Table 1

General Characteristics of Selected Measurements (N=24)

jkan-45-783-i001
Table 2

Characteristics of Measurements for Oxaliplatin Induced Peripheral Neuropathy (N=127)

jkan-45-783-i002

*If two or more of the measurements is used in one study, marked duplicately; †Not addressed the version used;

DEB-NTC=Neurotoxicity Criteria of Debiopharm; FGS=Functional Grading Scale; NCI-CTC=National Cancer Institute–Common Toxicity Criteria; NCI-CTCAE=National Cancer Institute–Common Toxicity Criteria Adverse Effect; NCI-SC=National Cancer Institute-Sanofi Criteria; NDS=Neurological Disability Score; NSS=Neuropathy Symptom Score; PNP=Peripheral neuropathy; WHO=World Health Organization; CIPNAT=Chemotherapy-induced Peripheral Neuropathy Assessment Tool; EORTC-QLQ-CIPN-20=European Organisation of Research and Treatment of Cancer-Quality of Life-chemotherapy induced peripheral neuropathy-20; FACT/GOG-Ntx-12=Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group–neurotoxicity-12; NPSI=Neuropathic Pain Symptom Inventory; OANQ=Oxaliplatin-associated Neuropathy Questionnaire; PNQ=Patient Neurotoxicity Questionnaire; TNS=Total Neuropathy Score; TNSc=Total Neuropathy Score Clinical version; TNSr=Total Neuropathy Score Reduced version.

Table 3

Summary of the Quality Assessment of the Oxaliplatin Induced Peripheral Neuropathy Measurements

jkan-45-783-i003

DEB-NTC=Neurotoxicity Criteria of Debiopharm; FGS=Functional Grading Scale; NCI-CTC=National Cancer Institute–Common Toxicity Criteria; NCI-CTCAE=National Cancer Institute–Common Toxicity Criteria Adverse Effect; NCI-SC=National Cancer Institute-Sanofi Criteria; NDS=Neurological Disability Score; NSS=Neuropathy Symptom Score; PNP=Peripheral neuropathy; WHO=World Health Organization; CIPNAT=Chemotherapy-induced Peripheral Neuropathy Assessment Tool; EORTC-QLQ-CIPN-20=European Organisation of Research and Treatment of Cancer-Quality of Life-chemotherapy induced peripheral neuropathy-20; FACT/GOG-Ntx-12=Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group–neurotoxicity-12; NPSI=Neuropathic Pain Symptom Inventory; OANQ=Oxaliplatin-associated Neuropathy Questionnaire; PNQ=Patient Neurotoxicity Questionnaire; TNS=Total Neuropathy Score; TNSc=Total Neuropathy Score Clinical version; TNSr=Total Neuropathy Score Reduced version.

Notes

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2014R1A1A3054386).

This study was supported by the research fund of Yonsei University College of Nursing (6-2012-0053).

CONFLICTS OF INTEREST The authors declared no conflict of interest.

Appendix

Appendix 1

Inclusion studies in this study

  1. Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A gynecologic oncology group study. Oncology Nursing Forum. 2004;31(3):615-623. http://dx.doi.org/10.1188/04.onf.615-623

  2. Antonacopoulou AG, Argyriou AA, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Integrin beta-3 L33P: A new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? European Journal of Neurology. 2010;17(7):963-968. http://dx.doi.org/10.1111/j.1468-1331.2010.02966.x

  3. Aparicio T, Desramé J, Lecomte T, Mitry E, Belloc J, Etienney I, et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. British Journal of Cancer. 2003;89(8):1439-1444. http://dx.doi.org/10.1038/sj.bjc.6601310

  4. Argyriou AA, Briani C, Cavaletti G, Bruna J, Alberti P, Velasco R, et al. Advanced age and liability to oxaliplatin-induced peripheral neuropathy: Post hoc analysis of a prospective study. European Journal of Neurology. 2013;20(5):788-794. http://dx.doi.org/10.1111/ene.12061

  5. Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438-444. http://dx.doi.org/10.1002/cncr.27732

  6. Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncologica. 2007;46(8):1131-1137. http://dx.doi.org/10.1080/02841860701355055

  7. Argyriou AA, Polychronopoulos P, Koutras A, Xiros N, Petsas T, Argyriou K, et al. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. European Journal of Cancer Care. 2007;16(3):231-237. http://dx.doi.org/10.1111/j.1365-2354.2006.00718.x

  8. Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): A prospective evaluation of 150 colorectal cancer patients. Annals of Oncology. 2012;23(12):3116-3122. http://dx.doi.org/10.1093/annonc/mds208

  9. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care in Cancer. 2011;19(6):833-841. http://dx.doi.org/10.1007/s00520-010-0911-0

  10. Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: A patient perspective. Supportive Care in Cancer. 2012;20(11):2959-2967. http://dx.doi.org/10.1007/s00520-012-1428-5

  11. Bennouna J, Perrier H, Paillot B, Priou F, Jacob JH, Hebbar M, et al. 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. British Journal of Cancer. 2006;94(1):69-73. http://dx.doi.org/10.1038/sj.bjc.6602913

  12. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the neuropathic pain symptom inventory. Pain. 2004;108(3):248-257. http://dx.doi.org/10.1016/j.pain.2003.12.024

  13. Burakgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology. 2011;77(10):980-986. http://dx.doi.org/10.1212/WNL.0b013e31822cfc59

  14. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, et al. Psychometric evaluation of the functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecological Cancer. 2003;13(6):741-748. http://dx.doi.org/10.1111/j.1525-1438.2003.13603.x

  15. Cals L, Rixe O, François E, Favre R, Merad L, Deplanque G, et al. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Annals of Oncology. 2004;15(7):1018-1024. http://dx.doi.org/10.1093/annonc/mdh259

  16. Caravatta L, Picardi V, Tambaro R, Padula GD, Macchia G, Deodato F, et al. Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: A dose-escalation study. American Journal of Clinical Oncology. 2012;35(5):424-431. http://dx.doi.org/10.1097/COC.0b013e31821a5844

  17. von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study. Investigational New Drugs. 2007;25(2):173-180. http://dx.doi.org/10.1007/s10637-006-9010-y

  18. Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, et al. Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Annals of Oncology. 2007;18(8): 1359-1362. http://dx.doi.org/10.1093/annonc/mdm160

  19. Carlomagno C, Matano E, Bianco R, Cimminiello C, Prudente A, Pagliarulo C, et al. Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors. Experimental and Therapeutic Medicine. 2010;1(4):611-617. http://dx.doi.org/10.3892/etm_00000096

  20. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology. 2002;20(16):3478-3483. http://dx.doi.org/10.1200/JCO.2002.07.061

  21. Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, et al. Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: Can it reduce neuropathy? Supportive Care in Cancer. 2010;18(10): 1263-1270. http://dx.doi.org/10.1007/s00520-009-0740-1

  22. Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. Journal of the National Cancer Institute. 1990;82(12): 1046-1050. http://dx.doi.org/10.1093/jnci/82.12.1046

  23. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology. 2003;61(9):1297-1300. http://dx.doi.org/10.1212/01.WNL.0000092015.03923.19

  24. Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, et al. Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System. 2006;11(2):135-141. http://dx.doi.org/10.1111/j.1085-9489.2006.00078.x

  25. Cavanna L, Artioli F, Codignola C, Lazzaro A, Rizzi A, Gamboni A, et al. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). American Journal of Clinical Oncology. 2006;29(4):371-375. http://dx.doi.org/10.1097/01.coc.0000221358.57089.f2

  26. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. Journal of the Peripheral Nervous System. 2008;13(4):275-282. http://dx.doi.org/10.1111/j.1529-8027.2008.00193.x

  27. Chay WY, Tan SH, Lo YL, Ong SY, Ng HC, Gao F, et al. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia-Pacific Journal of Clinical Oncology. 2010;6(4):270-277. http://dx.doi.org/10.1111/j.1743-7563.2010.01344.x

  28. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI treatment referral center trial TRC-0301. Journal of Clinical Oncology. 2006;24(21):3354-3360. http://dx.doi.org/10.1200/jco.2005.05.1573

  29. Chen JS, Chao Y, Yang TS, Chou WC, Chen LT, Lee KD, et al. A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma. Cancer Chemotherapy and Pharmacology. 2009;65(1):151-157. http://dx.doi.org/10.1007/s00280-009-1018-5

  30. Chen JS, Chen YY, Huang JS, Yeh KY, Chen PT, Shen WC, et al. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric Cancer. 2012;15(1):49-55. http://dx.doi.org/10.1007/s10120-011-0060-2

  31. Chiara S, Nobile MT, Gozza A, Taveggia P, Heouaine A, Pastrone I, et al. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer. Anticancer Research. 2004;24 (1):355-360.

  32. Comella P, Casaretti R, Crucitta E, De Vita F, Palmeri S, Avallone A, et al. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: A salvage regimen for colorectal cancer patients. British Journal of Cancer. 2002;86(12):1871-1875. http://dx.doi.org/10.1038/sj.bjc.6600414

  33. Conroy T, Paillot B, François E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a groupe tumeurs digestives of the federation nationale des centres de lutte contre le cancer study. Journal of Clinical Oncology. 2005;23(6):1228-1236. http://dx.doi.org/10.1200/jco.2005.06.050

  34. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et al. Total neuropathy score: Validation and reliability study. Neurology. 1999;53(8):1660-1664.

  35. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. British Journal of Cancer. 2005;92(9):1644-1649. http://dx.doi.org/10.1038/sj.bjc.6602573

  36. Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Annals of Oncology. 2002;13(2):258-266. http://dx.doi.org/10.1093/annonc/mdf018

  37. Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology. 2012;23(1):200-205. http://dx.doi.org/10.1093/annonc/mdr045

  38. Dyck PJ, Bushek W, Spring EM, Karnes JL, Litchy WJ, O'Brien PC, et al. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care. 1987;10(4):432-440. http://dx.doi.org/10.2337/diacare.10.4.432

  39. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ, 3rd. The Rochester diabetic neuropathy study: Reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42(6):1164-1170. http://dx.doi.org/10.1212/WNL.42.6.1164

  40. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Annals of Neurology. 1980;8(6):590-596. http://dx.doi.org/10.1002/ana.410080608

  41. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Seminars in Oncology. 1998;25 (2 Suppl 5):13-22.

  42. Farker K, Merkel U, Wedding U, Hippius M, Höffken K, Hoffmann A. Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: Original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. International Journal of Clinical Pharmacology and Therapeutics. 2006;44(1):31-37.

  43. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Seminars in Oncology. 2002;29(5 Suppl 15):21-33. http://dx.doi.org/10.1053/sonc.2002.35525

  44. Gérard JP, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 phase II trial. Journal of Clinical Oncology. 2003;21(6):1119-1124. http://dx.doi.org/10.1200/JCO.2003.10.045

  45. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology. 2004;22(1):23-30. http://dx.doi.org/10.1200/jco.2004.09.046

  46. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. Journal of Clinical Oncology. 2011;29(4):421-427. http://dx.doi.org/10.1200/jco.2010.31.5911

  47. Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: A phase 2 study. The Lancet Oncology. 2010;11(12):1142-1148. http://dx.doi.org/10.1016/s1470-2045(10)70247-3

  48. Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. British Journal of Cancer. 2006;95(7):848-852. http://dx.doi.org/10.1038/sj.bjc.6603334

  49. Hsieh RK, Chao TY, Chen WS, Yang TS, Chen LT, Chen PM, et al. Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens. Cancer Investigation. 2004;22(2):171-179. http://dx.doi.org/10.1081/CNV-120030204

  50. Hsuen Lim E, Seng Cheong Lim R, Seng Wu T, Loong Kong H. Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma: An Asian experience. The Annals of Pharmacotherapy. 2003;37(12):1909-1912. http://dx.doi.org/10.1345/aph.1D153

  51. Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: A gynecologic oncology group study. International Journal of Gynecological Cancer. 2007;17(2):387-393. http://dx.doi.org/10.1111/j.1525-1438.2007.00794.x

  52. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. The Lancet. 1978;2(8093):750-753.

  53. Inoue N, Ishida H, Sano M, Kishino T, Okada N, Kumamoto K, et al. Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. International Journal of Clinical Oncology. 2012;17(4):341-347. http://dx.doi.org/10.1007/s10147-011-0298-z

  54. Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clinical Colorectal Cancer. 2004;4(1):46-50. http://dx.doi.org/10.3816/CCC.2004.n.009

  55. Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, et al. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiology. 2010;34(2):189-193. http://dx.doi.org/10.1016/j.canep.2010.02.008

  56. Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T, et al. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anti-Cancer Drugs. 2010;21(9):877-881. http://dx.doi.org/10.1097/CAD.0b013e32833db89d

  57. Karlsson JO, Adolfsson K, Thelin B, Jynge P, Andersson RG, Falkmer UG. First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study. Translational Oncology. 2012;5(1):32-38.

  58. Kato K, Inaba Y, Tsuji Y, Esaki T, Yoshioka A, Mizunuma N, et al. A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer. Japanese Journal of Clinical Oncology. 2011;41(1): 63-68. http://dx.doi.org/10.1093/jjco/hyq158

  59. Kautio AL, Haanpää M, Kautiainen H, Leminen A, Kalso E, Saarto T. Oxaliplatin scale and national cancer institute-common toxicity criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Research. 2011;31(10):3493-3496.

  60. Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from national surgical adjuvant breast and bowel project trials C-07 and LTS-01. Cancer. 2012;118(22):5614-5622. http://dx.doi.org/10.1002/cncr.27593

  61. Kopec JA, Land SR, Cecchini RS, Ganz PA, Cella D, Costantino JP, et al. Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. The Journal of Supportive Oncology. 2006;4(8):W1-W8.

  62. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin and axonal Na+ channel function in vivo. Clinical Cancer Research. 2006;12(15):4481-4484. http://dx.doi.org/10.1158/1078-0432.ccr-06-0694

  63. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle and Nerve. 2005;32(1):51-60. http://dx.doi.org/10.1002/mus.20340

  64. Kuo DY, Blank SV, Christos PJ, Kim M, Caputo TA, Pothuri B, et al. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York cancer consortium study. Gynecologic Oncology. 2010;116(3):442-446. http://dx.doi.org/10.1016/j.ygyno.2009.10.082

  65. Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, et al. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Supportive Care in Cancer. 2009;17(8):1071-1080. http://dx.doi.org/10.1007/s00520-008-0550-x

  66. Kuroi K, Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, et al. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. Japanese Journal of Clinical Oncology. 2008;38(11):748-754. http://dx.doi.org/10.1093/jjco/hyn100

  67. Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. European Journal of Cancer. 2009;45(4):572-578. http://dx.doi.org/10.1016/j.ejca.2008.10.015

  68. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal of Clinical Oncology. 2007;25(16):2205-2211. http://dx.doi.org/10.1200/jco.2006.08.6652

  69. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clinical Cancer Research. 2006;12(10):3050-3056. http://dx.doi.org/10.1158/1078-0432.ccr-05-2076

  70. Lee KH, Kim MK, Kim YH, Ryoo BY, Lim HY, Song HS, et al. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: A multicenter phase II study. Cancer Chemotherapy and Pharmacology. 2009;64(2):317-325. http://dx.doi.org/10.1007/s00280-008-0873-9

  71. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005;5:116. http://dx.doi.org/10.1186/1471-2407-5-116

  72. Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992;69(4):893-900.

  73. Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, et al. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: Preliminary data. Supportive Care in Cancer. 2006;14(5):484-487. http://dx.doi.org/10.1007/s00520-006-0018-9

  74. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. Journal of Clinical Oncology. 2005;23(15):3509-3516. http://dx.doi.org/10.1200/jco.2005.06.023

  75. Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, et al. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer. Chemotherapy. 2008;54(3):228-235. http://dx.doi.org/10.1159/000140467

  76. Manzione L, Romano R, Germano D. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: A single-institution experience. Oncology. 2007;73(5-6):311-315. http://dx.doi.org/10.1159/000134239

  77. National Cancer Institute. NCI (National Cancer Institute) common toxicity criteria version 1 [Internet]. Bethesda, MD: Author; 1983 [cited 2012 December 16]. Available from: https://www.ucdmc.ucdavis.edu/clinicaltrials/StudyTools/Documents/NCI_Toxicity_Table.pdf.

  78. National Cancer Institute. Common toxicity criteria, version 2.0 [Internet]. Bethesda, MD: Author; 1999 [cited 2012 December 16]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcmanual_v4_10-4-99.pdf.

  79. Neri B, Pantaleo P, Giommoni E, Grifoni R, Paoletti C, Rotella V, et al. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: A phase II study. British Journal of Cancer. 2007;96(7):1043-1046. http://dx.doi.org/10.1038/sj.bjc.6603644

  80. Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, et al. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. International Journal of Clinical Oncology. 2011;16(4):322-327. http://dx.doi.org/10.1007/s10147-010-0183-1

  81. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mc-Fadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. American Journal of Clinical Oncology. 1982;5(6):649-655.

  82. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, et al. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer. 2005;104(4):781-787. http://dx.doi.org/10.1002/cncr.21219

  83. Oldenburg J, Fosså SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors. Quality of Life Research. 2006;15(5):791-800. http://dx.doi.org/10.1007/s11136-005-5370-6

  84. Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML, Kiernan MC. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology. 2009;27(8):1243-1249. http://dx.doi.org/10.1200/jco.2008.19.3425

  85. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Long-term neuropathy after oxaliplatin treatment: Challenging the dictum of reversibility. The Oncologist. 2011; 16(5):708-716. http://dx.doi.org/10.1634/theoncologist.2010-0248

  86. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity. Oncology. 2009;77(6):342-348. http://dx.doi.org/10.1159/000265940

  87. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy. Brain. 2009;132(Pt 10):2712-2723. http://dx.doi.org/10.1093/brain/awp219

  88. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: A phase II study. Annals of Oncology. 2004;15(3):493-497. http://dx.doi.org/10.1093/annonc/mdh103

  89. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Annals of Neurology. 1994;35(3):304-311. http://dx.doi.org/10.1002/ana.410350310

  90. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the eastern cooperative oncology group. Journal of Clinical Oncology. 2009;27(23):3778-3785. http://dx.doi.org/10.1200/jco.2008.20.9007

  91. Porta C, Zimatore M, Imarisio I, Natalizi A, Sartore-Bianchi A, Danova M, et al. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: Final results of a single-institution Phase II study. Cancer. 2004;100(10):2132-2138. http://dx.doi.org/10.1002/cncr.20226

  92. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer. 2005;41(8):1135-1139. http://dx.doi.org/10.1016/j.ejca.2005.02.012

  93. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Annals of Oncology. 1998;9(7):739-744.

  94. Ramanathan RK, Rothenberg ML, de Gramont A, Tournigand C, Goldberg RM, Gupta S, et al. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: A pooled analysis of three phase III studies. Annals of Oncology. 2010;21(4):754-758. http://dx.doi.org/10.1093/annonc/mdp509

  95. Recchia F, Candeloro G, Guerriero G, Piazze J, Desideri G, Necozione S, et al. Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlier. Anti-Cancer Drugs. 2010;21(5):559-564. http://dx.doi.org/10.1097/CAD.0b013e328338b6a5

  96. Salah-Eldin MA, Wahba HA, Halim AA. Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: A phase II study. Indian Journal of Cancer. 2012;49(1):169-175. http://dx.doi.org/10.4103/0019-509x.98944

  97. Schöffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Annals of Oncology. 2004;15(4):671-679. http://dx.doi.org/10.1093/annonc/mdh141

  98. Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clinical Lung Cancer. 2003;4(5):294-297. http://dx.doi.org/10.3816/CLC.2003.n.009

  99. Seitz JF, Bennouna J, Paillot B, Gamelin E, François E, Conroy T, et al. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Annals of Oncology. 2002;13(7):1072-1079. http://dx.doi.org/10.1093/annonc/mdf183

  100. Shao YY, Hu FC, Liang JT, Chiu WT, Cheng AL, Yang CH. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. Journal of the Formosan Medical Association. 2010;109(5):362-368. http://dx.doi.org/10.1016/s0929-6646(10)60064-2

  101. Shibata Y, Ariyama H, Baba E, Takii Y, Esaki T, Mitsugi K, et al. Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. International Journal of Clinical Oncology. 2009;14(5):397-401. http://dx.doi.org/10.1007/s10147-009-0883-6

  102. Shimizu T, Satoh T, Tamura K, Ozaki T, Okamoto I, Fukuoka M, et al. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: Post-approval Japanese population experience. International Journal of Clinical Oncology. 2007;12(3):218-223. http://dx.doi.org/10.1007/s10147-007-0658-x

  103. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Supportive Care in Cancer. 2009;17(12):1483-1491. http://dx.doi.org/10.1007/s00520-009-0613-7

  104. Shirao K, Matsumura Y, Yamada Y, Muro K, Gotoh M, Boku N, et al. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. Japanese Journal of Clinical Oncology. 2006;36(5):295-300. http://dx.doi.org/10.1093/jjco/hyl016

  105. Shord SS, Bernard SA, Lindley C, Blodgett A, Mehta V, Churchel MA, et al. Oxaliplatin biotransformation and pharmacokinetics: A pilot study to determine the possible relationship to neurotoxicity. Anticancer Research. 2002;22(4):2301-2309.

  106. Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, et al. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. Journal of Clinical Oncology. 2010;28(13):2213-2219. http://dx.doi.org/10.1200/jco.2009.24.8773

  107. Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J. Liposomal oxaliplatin in the treatment of advanced cancer: A phase I study. Anticancer Research. 2006;26(2B):1489-1493.

  108. Taïeb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer. 2003;98(12):2664-2670. http://dx.doi.org/10.1002/cncr.11869

  109. Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: Atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer. 2002;94(9): 2434-2440. http://dx.doi.org/10.1002/cncr.10500

  110. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: A national cancer institute organ dysfunction working group study. Journal of Clinical Oncology. 2003;21(14):2664-2672. http://dx.doi.org/10.1200/jco.2003.11.015

  111. Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clinical Journal of Oncology Nursing. 2011;15(2):182-188. http://dx.doi.org/10.1188/11.cjon.182-188

  112. Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer. 2012;20(3):583-589. http://dx.doi.org/10.1007/s00520-011-1127-7

  113. Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nursing. 2011;34(4):E10-E20. http://dx.doi.org/10.1097/NCC.0b013e31820251de

  114. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. Journal of Clinical Oncology. 2006;24(3):394-400. http://dx.doi.org/10.1200/jco.2005.03.0106

  115. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology. 2003;13(3):176-181. http://dx.doi.org/10.1016/s1053-4296(03)00031-6

  116. Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Investigational New Drugs. 2005;23(4):369-375. http://dx.doi.org/10.1007/s10637-005-1446-y

  117. Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, et al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Annals of Oncology. 2006;17(Suppl 7):vii68-vii72. http://dx.doi.org/10.1093/annonc/mdl955

  118. Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Annals of Oncology. 2006;17(3):429-436. http://dx.doi.org/10.1093/annonc/mdj097

  119. Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, et al. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Annals of Oncology. 2004;15(6):915-920. http://dx.doi.org/10.1093/annonc/mdh215

  120. World Health Organization. WHO handbook for reporting results of cancer treatment [Internet]. Geneva, CH: Author; 1979 [cited 2012 December 18]. Available from: http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf.

  121. Wu Z, Ouyang J, He Z, Zhang S. Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: A systematic review and meta-analysis. European Journal of Cancer. 2012;48(12):1791-1798. http://dx.doi.org/10.1016/j.ejca.2012.03.018

  122. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008;113(8):2046-2052. http://dx.doi.org/10.1002/cncr.23810

  123. Yang TS, Chen JS, Tang R, Chiang JM, Hsieh PS, Yeh CY, et al. Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: A dose-finding study. Anti-Cancer Drugs. 2003;14(2):145-151. http://dx.doi.org/10.1097/01.cad.0000054525.51553.33

  124. Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, et al. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: An open-label pilot study. Supportive Care in Cancer. 2012;20(7):1491-1497. http://dx.doi.org/10.1007/s00520-011-1237-2

  125. Ychou M, Conroy T, Seitz JF, Gourgou S, Hua A, Mery-Mignard D, et al. An open phase I study assessing the feasibility of the triple combination: Oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Annals of Oncology. 2003;14(3):481-489. http://dx.doi.org/10.1093/annonc/mdg119

  126. Zampino MG, Magni E, Massacesi C, Zaniboni A, Martignetti A, Zorzino L, et al. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer. 2007;110(4):752-758. http://dx.doi.org/10.1002/cncr.22851

  127. Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, et al. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. Journal of Clinical Oncology. 2002;20(10):2551-2558. http://dx.doi.org/10.1200/JCO.2002.06.164

References

1. Bécouarn Y, Agostini C, Trufflandier N, Boulanger V. Oxaliplatin: Available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol. 2001; 40(3):265–272. DOI: 10.1016/S1040-8428(01)00169-X.
2. Otsu S, Hirashima Y, Nishikawa K, Sakashita H, Morinaga R, Watanabe K, et al. Neurological toxicity in metastatic colorectal cancer patients treated with modified FOLFOX6 plus bevacizumab. Jpn Clin Med. 2014; 5:19–23. DOI: 10.4137/jcm.s15553.
3. Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol. 2007; 3(2):281–294. DOI: 10.1517/17425255.3.2.281.
4. Zedan AH, Hansen TF, Fex Svenningsen A, Vilholm OJ. Oxaliplatin-induced neuropathy in colorectal cancer: Many questions with few answers. Clin Colorectal Cancer. 2014; 13(2):73–80. DOI: 10.1016/j.clcc.2013.11.004.
5. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005; 5:116. DOI: 10.1186/1471-2407-5-116.
6. Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol. 2004; 22(23):4753–4761. DOI: 10.1200/jco.2004.03.119.
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938–2947.
8. Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, et al. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer. 2012; 11(2):93–100. DOI: 10.1016/j.clcc.2011.10.004.
9. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014; 32(10):997–1005. DOI: 10.1200/jco.2013.52.0536.
10. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology. 2003; 61(9):1297–1300. DOI: 10.1212/01.WNL.0000092015.03923.19.
11. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998; 9(7):739–744.
12. Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs. 2011; 34(4):E10–E20. DOI: 10.1097/NCC.0b013e31820251de.
13. Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: A patient perspective. Support Care Cancer. 2012; 20(11):2959–2967. DOI: 10.1007/s00520-012-1428-5.
14. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009; 17(12):1483–1491. DOI: 10.1007/s00520-009-0613-7.
15. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005; 5:Suppl 1. S38–S46. DOI: 10.3816/CCC.2005.s.006.
16. Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G, et al. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the national cancer institutesponsored clinical trials networks. J Clin Oncol. 2007; 25(32):5070–5077. DOI: 10.1200/jco.2007.12.7670.
17. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010; 6(12):657–666. DOI: 10.1038/nrneurol.2010.160.
18. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007; 60(1):34–42. DOI: 10.1016/j.jclinepi.2006.03.012.
19. Windle G, Bennett KM, Noyes J. A methodological review of resilience measurement scales. Health Qual Life Outcomes. 2011; 9:8. DOI: 10.1186/1477-7525-9-8.
20. Larsen CM, Juul-Kristensen B, Lund H, Søgaard K. Measurement properties of existing clinical assessment methods evaluating scapular positioning and function. A systematic review. Physiother Theory Pract. 2014; 30(7):453–482. DOI: 10.3109/09593985.2014.899414.
21. Silva PF, Quintino LF, Franco J, Faria CD. Measurement properties and feasibility of clinical tests to assess sit-to-stand/stand-tosit tasks in subjects with neurological disease: A systematic review. Braz J Phys Ther. 2014; 18(2):99–110. DOI: 10.1590/S1413-35552012005000155.
22. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990; 8(2):147–159.
23. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006; 33(1):15–49. DOI: 10.1053/j.seminoncol.2005.12.010.
24. Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992; 69(4):893–900. DOI: 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X.
25. Kautio AL, Haanpää M, Kautiainen H, Leminen A, Kalso E, Saarto T. Oxaliplatin scale and national cancer institute-common toxicity criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Res. 2011; 31(10):3493–3496.
26. Smith EM, Beck SL, Cohen J. The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008; 35(1):96–102. DOI: 10.1188/08.onf.96-102.
27. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer. 2005; 41(8):1135–1139. DOI: 10.1016/j.ejca.2005.02.012.
28. Lee EH, Kim CJ, Kim EJ, Chae HJ, Cho SY. Measurement properties of self-report questionnaires published in Korean nursing journals. J Korean Acad Nurs. 2013; 43(1):50–58. DOI: 10.4040/jkan.2013.43.1.50.
29. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. COSMIN checklist manual [Internet]. Amsterdam, NL: COSMIN Group;2012. cited 2015 January 17. Available from: http://www.cosmin.nl/images/upload/files/COSMIN%20checklist%20manual%20v9.pdf.
TOOLS
Similar articles